Top

Published in:

01-12-2005 | Topic Paper

Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors

Authors: Frank Sommer, Wolfgang Schulze

Published in: World Journal of Urology | Issue 6/2005

Abstract

A large body of evidence has accumulated demonstrating that a common pathway in conditions such as hypertension, atherosclerosis, hypercholesterolemia, diabetes mellitus, and erectile dysfunction (ED) is endothelial dysfunction. Although a complete pharmacological cure for ED is currently unavailable, the phosphodiesterase 5 (PDE5) inhibitors sildenafil, vardenafil, and tadalafil are efficacious oral therapy for ED. Results from recent studies suggest that regular treatment with a PDE5 inhibitor may lead to enhanced erectile function (EF) beyond that observed with on-demand usage, possibly through improvement of endothelial function. Such an effect may be viewed as rehabilitation of damaged erectile tissue. The present review focuses on several recent studies which provide evidence for the beneficial effect of regular PDE5 inhibitor administration on the improvement of EF by rehabilitation of vascular endothelium.

Verma S, Buchanan MR, Anderson TJ (2003) Endothelial function as a biomarker of vascular disease. Circulation 108:2054–2059CrossRefPubMed

Kloner RA, Speakman M (2002) Erectile dysfunction and atherosclerosis. Curr Atheroscler Rep 4:397–401PubMedCrossRef

Soloman H, Man JW, Jackson G (2003) Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart 89:251–254CrossRefPubMed

Rosen MP, Greenfield AJ, Walker TG, et al (1991) Cigarette smoking: an independent risk factor for atherosclerosis in the hypogastric-cavernous arterial bed of men with atherogenic impotence. J Urol 145:759–763PubMed

Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, Mc Kinlay JB (1994) Impotence and its medical and psychological correlates: results of the Massachusetts Male Aging Study. J Urol 151:54–61PubMed

Lue T (2000) Erectile dysfunction. N Engl J Med 342:1802–1813CrossRefPubMed

Sullivan ME, Thompson CS, Dashwood MR, Khan MA, Jeremy JY, Morgan RJ, Mikhailidis DP (1999) Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease? Cardiovasc Res 43:658–665CrossRefPubMed

Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U (2000) Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey’. Int J Impot Res 12(6):305–311CrossRefPubMed

Jardin A, Wagner G, Khoury S et al (1999) Recommendations of the 1st International Consultation on Erectile Dysfunction. Co-sponsored by the World Health Organization (WHO), International Consultation on Urological Diseases (ICUD) and Societe Internationale d’Urologie (SIU) and held July 1–3, 1999, Paris, 2000, p 713

10.

Aytac IA, McKinlay JB, Krane RJ (1999) The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 84:50–56CrossRefPubMed

11.

Montorsi F, Briganti A, Salonia A, et al (2003) Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 44:360–365CrossRefPubMed

12.

Saenz de Tejada I, Gonzales Cadavid N, Heaton JP, et al (2000) Anatomy, physiology and pathophysiology of erectile dysfunction. In: Jardin A, Wagner G, Khoury S, Giuliano F, Padma-Nathan H, Rosen RC (eds) Erectile dysfunction. Health Publications Ltd., Plymouth, pp 65–102

13.

Terradas C, Levalle O, Nagelberg A, Mormandi E (2001) Sildenafil improves nocturnal penile erections in organic impotence. Int J Impot Res 13(2):125–129CrossRefPubMed

14.

Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM (1998) Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 159:2164–2171CrossRefPubMed

15.

Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H, Vardenafil Study Group (2003) Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 61(4 Suppl. 1):8–14CrossRefPubMed

16.

Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker WA, et al (1998) Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 338:1397–1404CrossRefPubMed

17.

Brock GB, McMahon CG, Chen KK, Costigan T, Shen W, Watkins V, Anglin G, Whitaker S (2002) Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 168(4 Pt 1):1332–1336CrossRefPubMed

18.

Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA (2002) Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 25(8):1336–1339PubMedCrossRef

19.

Montorsi F, Maga T, Strambi LF, et al (2000) Sildenafil taken at bedtime significantly increases nocturnal erections: results of a placebo-controlled study. Urology 56(6):906–911CrossRefPubMed

20.

Rochira V, Granata AR, Balestrieri A, Madeo B, Carani C (2002) Effects of sildenafil on nocturnal penile tumescence and rigidity in normal men: randomized, placebo-controlled, crossover study. J Androl 23(4):566–571PubMed

21.

El Galley R, Rutland H, Talic R, Keane T, Clark H (2001) Long-term efficacy of sildenafil and tachyphylaxis effect. J Urol 166:927–931CrossRefPubMed

22.

Behr-Roussel D, Gorny D, Mevel K, Caisey S, Bernabé J, Burgess G, Wayman C, Alexandre L, Giuliano F (2005) Chronic sildenafil improves erectile function and endothelium-dependent cavernosal relaxations in rats: lack of tachyphylaxis. Eur Urol 47:87–91CrossRefPubMed

23.

Rosano GMC, Aversa A, Vitale C, Fabbri A, Fini M, Spera G (2005) Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 47:214–222CrossRefPubMed

24.

Caretta N, Palego P, Ferlin A, Garolla A, Bettella A, Selice R, Foresta C (2005) Resumption of spontaneous erections in selected patients affected by erectile dysfunction and various degrees of carotid wall alteration: role of tadalafil. Eur Urol 48:326–332CrossRefPubMed

25.

Porst H. Salvagetherapie mit täglicher Dosierung von Sildenafil bei Non-Respondern auf on demand Therapie mit 100 mg Sildenafil. Presented at the 55th Congress of the German Urological Association, Hamburg, Germany, 24–27 September 2003

26.

Porst H, van Ahlen H (1988) Stellenwert nächtlicher peniler Tumeszenz- und Rigiditätsmessungen (NPT) mit dem Rigiscan^® bei erektiler Dysfunktion. Aktuel Urol 19:21–25CrossRef

27.

Kim N, Vardi Y, Padma-Nathan H, Daley J, Goldstein I, Saenz de Tejada I (1993) Oxygen tension regulates the nitric oxide pathway. Physiological role in penile erection. J Clin Invest 91(2):437–442PubMed

28.

Foresta C, Caretta N, Lana A, Cabrelle A, Palu G, Ferlin A (2005) PDE-5 inhibitor, vardenafil, increases circulating progenitor cells in humans. Int J Impot Res 17(4):377–380CrossRefPubMed

29.

Aicher A, Heeschen C, Dimmeler S (2004) The role of NOS3 in stem cell mobilization. Trends Mol Med 10:421–425CrossRefPubMed

30.

Foresta C, Caretta N, Lana A, Cabrelle A, Palu G, Ferlin A (2005) Circulating progenitor cells in subjects with erectile dysfunction. Int J Impot Res 17(3):288–290CrossRefPubMed

31.

Ornish D, Brown SE, Scherwitz LW, et al (1990) Can lifestyle changes reverse coronary heart disease? The lifestyle heart trial. Lancet 336(8708):129–133CrossRefPubMed

Title: Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors
Authors: Frank Sommer
Wolfgang Schulze
Publication date: 01-12-2005
Publisher: Springer-Verlag
Published in: World Journal of Urology / Issue 6/2005
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-005-0021-7

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2005

Fascicular anatomy and surgical access of the human pudendal nerve

Cyclic AMP-specific and cyclic GMP-specific phosphodiesterase isoenzymes in human cavernous arteries—immunohistochemical distribution and functional significance

Distribution and functional significance of phosphodiesterase isoenzymes in the human lower urinary tract

Follow-up of men obtaining a six-core versus a ten-core benign prostate biopsy 7 years previously

Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction

Editorial